Novo Nordisk (NVO) Stock May Trade Below Fair Value After GLP 1 Expansion Plans

Novo Nordisk has seen its share price fall sharply in recent years, and the drop is prompting fresh questions about what investors are currently paying for its earnings. With the stock under pressure and growth ambitions around weight-loss treatments in focus, the valuation now hinges on how resilient and repeatable those profits look.

• Over the past 3 years the stock has fallen 59.8%, which puts the spotlight firmly on whether the current share price still lines up with the earnings power of the business.
• Recent news highlighting Novo Nordisk's shift toward GLP-1 weight-loss drugs, along with plans to launch multiple new treatments by 2030, can reshape expectations for future profit levels and the timing of cash flows tied to its research spend.
• Your read on Novo Nordisk is one view; the desks covering it have another. See what analysts think Novo Nordisk's shares could be worth.

The stock's next move may depend on whether Novo Nordisk's current price can be explained by the earnings it is generating today and is expected to produce in the years ahead.

If you are reassessing Novo Nordisk on its earnings, it can help to view it alongside other companies using a focused screen such as 28 high quality undervalued stocks.

Is Novo Nordisk a Bargain on Earnings?

P/E works well for Novo Nordisk because investors are fixated on what they are paying for each unit of earnings from its weight-loss and diabetes portfolio. Right now the stock trades on a P/E of 9.7x. That compares with a pharmaceuticals industry average of about 15.3x and a peer group closer to 57.8x, so the headline earnings multiple looks low against both the wider sector and direct rivals.

Because the recent share price slump has arrived alongside intense focus on GLP-1 plans out to 2030, the gap to a more tailored fair multiple suggests Novo Nordisk currently screens undervalued on this metric. The fair P/E benchmark, which blends factors such as growth profile, profitability and risk, sits meaningfully above the current 9.7x, which implies the market is pricing its earnings stream more cautiously than that framework would suggest. Despite the recent concerns flagged in news flow about the business pivoting around weight-loss drugs, the P/E still places Novo Nordisk at a discount to both peers and this modelled fair level. Explore the numbers behind Novo Nordisk's P/E valuation.

The Novo Nordisk Narrative: What Would Justify Today's Price?

Novo Nordisk's Simply Wall St Narratives pick up where the P/E puzzle leaves off by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth far more or far less than it is today, and these storylines sit on the Community page. Each one treats fair value as a hypothesis about Novo Nordisk's business that you can watch over time rather than a one off snapshot.

One of the top community narratives on Novo Nordisk: 59% undervalued

"Current sentiment has swung deeply negative, but expectations are now low, and the pipeline beyond Wegovy is being valued at or near zero..."

Discover why this Narrative puts Novo Nordisk at 59% undervalued.

Novo Nordisk’s price is only one piece of the decision

Valuation can look compelling on paper, yet our checks have also highlighted specific areas of concern that deserve attention before you commit fresh capital or walk away. Take a closer look at 2 warning signs (1 major) before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com